RASGEF1A and non-small cell lung carcinoma: Our model identified 36 upregulated genes, including the top 10 (GSTT2B, HMGA2, AC135050.2, ANKRD33B, MMP13, PLA2G2D, RASGEF1A, BIRC7, DCAF4L2, and CHMP7), which were associated with positive responses to PD-1 immunotherapy in patients with NSCLC.